Solution-type quetiapine composition for intranasal administration and use thereof

HK40137544APending Publication Date: 2026-09-11SICHUAN PURITY PHARM CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
HK62026127172
Authority / Receiving Office
HK · HK
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-12-29
Filing Date
2026-08-06
Publication Date
2026-09-11

Smart Images

  • Figure 00000000_0000_ABST
    Figure 00000000_0000_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of pharmaceutical preparations, and provides a novel solution type nasal administration composition of quetiapine. In the provided composition, quetiapine is completely dissolved in the composition in the form of a solution, and is administered via the nose. The quetiapine solution type nasal preparation provided by the invention has especially useful pharmacokinetic and pharmacodynamic characteristics compared with oral dosage forms on the market. Compared with other disclosed nasal nano-emulsion forms, the nasal nano-emulsion still has surprising pharmacokinetic and pharmacodynamic characteristics, shows good clinical application prospects, and is expected to meet unsatisfied clinical requirements. On the basis, the invention also provides a further improved technical scheme of high saturated dissolution concentration and a further improved technical scheme of good chemical stability for preparing the quetiapine solution type nasal preparation.
Need to check novelty before this filing date? Find Prior Art

Description

(19) State Intellectual Property Office (12) Invention Patent Application (10) Application Publication Number (43) Application Publication Date (21) Application Number 202480060244.0 (22) Application Date 2024.12.27 (66) Domestic Priority Data 202311871438.2 2023.12.29 CN (85) PCT International Application Entering National Phase Date 2026.03.19 (86) PCT International Application Application Data PCT / CN2024 / 143117 2024.12.27 (87) PCT International Application Publication Data WO2025 / 140529 ZH 2025.07.03 (71) Applicant Sichuan Prite Pharmaceutical Co., Ltd. Address 610096 No. 566, Antai Fifth Road, High-tech Zone, Chengdu, Sichuan Province (72) Inventors: Han Miao, Zhang Wenlong, Wang Wanshi, Xin Yue, Zhang Bin, Wang Zhenyu (74) Patent Agency: Beijing Xinno Chuangcheng Intellectual Property Agency Co., Ltd. 11728 Patent Attorney: Chen Yuejun (51) Int.Cl. A61K 9 / 08 (2006.01) A61K 31 / 554 (2006.01) A61K 47 / 00 (2006.01) A61K 47 / 10 (2006.01) A61K 47 / 18 (2006.01) A61K 47 / 36 (2006.01) A61P 25 / 18 (2006.01) (54) Invention Title: A Solution-Type Nasal Composition for Quetiapine and Its Application (57) Abstract: This invention belongs to the field of pharmaceutical formulation technology and provides a novel solution-type nasal composition for quetiapine. In the provided composition, quetiapine is completely dissolved in solution and administered nasally. Compared to marketed oral dosage forms, the provided quetiapine solution-type nasal formulation has particularly useful pharmacokinetic and pharmacodynamic characteristics. Compared to other disclosed nasal nanoemulsion forms, it still possesses surprising pharmacokinetic and pharmacodynamic characteristics, demonstrating good clinical application prospects and potentially meeting unmet clinical needs. Based on this, the invention also provides a further improved high-saturation dissolution concentration technique for preparing the quetiapine solution-type nasal formulation and a further improved good chemical stability technique. CN 121969353 A 2026.05.01 CN 1 21 96 93 53 A The present disclosure pertains to the technical field of pharmaceutical preparations, and provides a novel solution-type quetiapine composition for intranasal administration. In the provided composition, quetiapine is completely dissolved therein in the form of a solution, and administered intranasally. Compared with the commercially available oral dosage forms, the provided solution-type quetiapine intranasal preparation has particularly useful pharmacokinetic and pharmacodynamic profiles. Compared with other disclosed forms such as intranasal nano-emulsion forms, the composition of the present disclosure still has surprising pharmacokinetic and pharmacodynamic profiles, exhibits promising clinical application prospects, and is expected to address unmet clinical needs.On this basis, the present disclosure further provides an improved high-saturation solubility technical solution and an improved technical solution of good chemical stability for the preparation of the solution-type quetiapine intranasal preparation. Abstract.

Claims

A quetiapine nasal administration composition, characterized in that: The composition includes quetiapine or a pharmaceutically acceptable salt thereof, and is in the form of a solution. The composition according to claim 1, characterized in that: The quetiapine content in the composition, calculated as free base, is 0.22-11.7% or 4.3-11.7% by mass. Alternatively, preferably, quetiapine is dissolved in the composition in the form of fumarate, and the quetiapine fumarate content in the composition is 0.25-13.4%, 0.25-5%, 0.25-1.7%, 5-13.4%, 5-9.7%, 5-7%, 0.25%, 1.7%, 5%, 5.2%, 6%, 6.5%, 6.6%, 6.7%, 7%, 8.2%, 9.5%, 9.7%, 13%, 13.3%, or 13.4% by mass. The composition according to claim 1, characterized in that: It also includes one or more combinations of solubilizers, cosolvents, thickeners, stabilizers, preservatives, pH adjusters, and pH buffers. The composition according to claim 3, characterized in that: The solubilizer may be selected from one or more combinations of benzyl alcohol, DMA, cyclodextrin, and surfactants; the cyclodextrin may be selected from one or more combinations of β-cyclodextrin, hydroxypropyl-β-cyclodextrin, and sulfobutyl-β-cyclodextrin; the surfactant may be selected from one or more combinations of Tween, Span, carbomer, and polyethylene glycol-15-hydroxystearate; the cosolvent may be selected from saturated alcohols; the saturated alcohol may be selected from one or more combinations of propylene glycol, ethanol, and glycerin; the thickener may be selected from one or more combinations of polyethylene glycol, pectin, cellulose, polyethylene hydrocarbon, and polyacrylic acid; the stabilizer may be selected from edetic acid. Salts, edetates, may include EDTA-2Na and / or EDTA-2K; preservatives may include benzalkonium chloride, benzalkonium bromide, benzyl chloride, potassium sorbate, methylparaben, ethylparaben, propylparaben, butylparaben, isopropylparaben, isobutylparaben, sodium propylparaben, and / or sodium methylparaben; pH adjusters may include one or more combinations of citric acid, hydrochloric acid, sodium hydroxide, potassium hydroxide, and meglumine; pH buffers may include one or more combinations of citrate buffers, phosphate buffers, and acetate buffers. The composition according to claim 1, characterized in that: It also includes a solubilizer, a co-solvent, a thickener, and water; the solubilizer is benzyl alcohol, and the mass percentage of benzyl alcohol in the composition can be selected from 1-10%, 1-9.3%, 5-9.3%, 1%, 3.2%, 5%, 7.5%, or 9.3%; the co-solvent is one or a combination of two or more of propylene glycol, ethanol, and glycerol, preferably propylene glycol; wherein: the mass percentage of propylene glycol in the composition can be selected from 0-12%, 4.6-12%, 6-12%, 4.6%, 4.7%, 5%, 6%, 10%, 11%, or 12%, and the mass percentage of ethanol in the composition can be selected from 0-20%, 6-20%, 0-19%. The composition contains 0.8%, 18.3-19.8%, 6%, 10%, 18.3%, 18.5%, or 19.8% by mass, and the glycerol content in the composition can be selected as 0-5%, 0-3%, 0-2.5%, 0-2.2%, or 2.2% by mass; the thickener is polyethylene glycol, preferably PEG3350 or PEG400; wherein the PEG3350 content in the composition can be selected as 0-20%, 2.5%-15%, 5-15%, 2.5%, 4.6%, 4.7%, 5%, 15%, or 20% by mass, and the PEG400 content in the composition can be selected as 0-15%, 10%, or 15% by mass. The composition according to claim 5, characterized in that: It also includes one or more of the following: stabilizers, preservatives, pH adjusters, and pH buffers; the stabilizer is EDTA-2Na, and the mass percentage of EDTA-2Na in the composition can be selected as 0-0.1% or 0.05%; the preservative is benzalkonium chloride, and the mass percentage of benzalkonium chloride in the composition can be selected as 0-0.02% or 0.02%; the pH adjuster is one or more of the following: citric acid, hydrochloric acid, sodium hydroxide, and meglumine, and the pH adjuster adjusts the pH value of the composition to 4.1-6.0, 4.5-6.0, 5.0-6.0, 4.1, 4.5, 4.9, 5.0, 5.1, 5.3, or 6.0; the pH buffer is a citrate buffer, a phosphate buffer, or an acetate buffer. A nasal composition for increasing the concentration of quetiapine, characterized in that: The composition includes quetiapine or a pharmaceutically acceptable salt thereof, and is a solution, and also includes a solubilizer. The composition according to claim 7, characterized in that: Solubilizers include one or more of benzyl alcohol, DMA, cyclodextrin, and surfactants. The composition according to claim 7, characterized in that: Solubilizers include benzyl alcohol and / or DMA. The composition according to claim 7, characterized in that: The solubilizer includes benzyl alcohol, and the mass percentage of benzyl alcohol in the composition can be selected as 1-10%, 3.2-10%, 5-10%, 5-9.3%, 5-7.5%, 1%, 3.2%, 5%, 7.5%, 9.3%, or 10%; optionally, the mass ratio of benzyl alcohol to quetiapine in the composition is 1:0.8 to 1.

2. The composition according to claim 10, characterized in that: The solubilizer in the composition may be only benzyl alcohol, or the solubilizer in the composition may be only benzyl alcohol and cyclodextrin, or the solubilizer in the composition may be only benzyl alcohol and surfactant, or the solubilizer in the composition may be only benzyl alcohol, cyclodextrin and surfactant. The composition according to claim 10, characterized in that: The composition also includes a cosolvent, which may include a saturated alcohol. The saturated alcohol may include one or more of propylene glycol, ethanol, and glycerol, preferably propylene glycol or a combination of propylene glycol and ethanol. The mass percentage of propylene glycol in the composition may be 0-12%, 4.6-12%, 6-12%, 4.6%, 4.7%, 5%, 6%, 10%, 11%, or 12%. The mass percentage of ethanol in the composition may be 0-20%, 6-20%, 0-19.8%, 18.3-19.8%, 6%, 10%, 18.3%, 18.5%, or 19.8%. The mass percentage of glycerol in the composition may be 0-5%, 0-3%, 0-2.5%, 0-2.2%, or 2.2%. The composition according to claim 10, characterized in that: It also includes surfactants and / or polyethylene glycol, and preferably includes one or more combinations of Tween, PEG3350 and PEG400, wherein Tween includes Tween 80 or Tween 20; wherein: the mass percentage of PEG3350 in the composition can be selected from 0-20%, 2.5%-15%, 5-15%, 2.5%, 4.6%, 4.7%, 5%, 15% or 20%; the mass percentage of PEG400 in the composition can be selected from 0-15%, 10% or 15%; and the mass percentage of Tween in the composition can be selected from 0-1.5%, 0.5%, 1%, 1.4% or 1.5%. The composition according to claim 8, characterized in that: Cyclodextrin includes one or more of β-cyclodextrin, hydroxypropyl-β-cyclodextrin and sulfobutyl-β-cyclodextrin, and the mass percentage of cyclodextrin in the composition can be selected as 0-10%, 1-5% or 5%. The composition according to claim 7, characterized in that: The concentration of quetiapine in the composition, calculated as free base, is 4.3-11.7% or 5.6-11.7% by mass; or, preferably, quetiapine is dissolved in the composition in the form of fumarate, wherein the mass percentage of quetiapine fumarate in the composition is 5-13.4%, 5-9.7%, 5-7%, 5%, 5.2%, 6%, 6.5%, 6.6%, 6.7%, 7%, 8.2%, 9.5%, 9.7%, 13%, 13.3%, or 13.4%. The composition according to any one of claims 7-15 is characterized in that: It also includes water, and one or more of the following: thickeners, stabilizers, preservatives, pH adjusters, and pH buffers. A stable nasal administration composition, characterized in that, The composition is a solution comprising water and the following components: The composition according to claim 17, characterized in that: The quetiapine content in the composition, calculated as free base, is 4.3-11.7% by mass; or, preferably, quetiapine is dissolved in the composition in the form of fumarate, wherein the quetiapine fumarate content in the composition is 0.25-13.4%, 0.25-5%, 0.25-1.7%, 5-13.4%, 5-9.7%, 5-7%, 0.25%, 1.7%, 5%, 5.2%, 6%, 6.5%, 6.6%, 6.7%, 7%, 8.2%, 9.5%, 9.7%, 13%, 13.3%, or 13.4% by mass. The composition according to claim 17, characterized in that: The solubilizer includes one or more of benzyl alcohol, cyclodextrin, Tween, and polyethylene glycol-15-hydroxystearate, wherein the cyclodextrin may include hydroxypropyl-β-cyclodextrin, and the Tween may include Tween 80 and / or Tween 20; wherein the mass percentage of benzyl alcohol in the composition may be 1-10%, 1-9.3%, 5-9.3%, 1%, 3.2%, 5%, 7.5%, or 9.3%, the mass percentage of cyclodextrin in the composition may be 0-5% or 5%, the mass percentage of Tween in the composition may be 0-1.4%, 1%, or 1.4%, and the mass percentage of polyethylene glycol-15-hydroxystearate in the composition may be 0-3%, 1.5%, or 3%. The composition according to claim 17, characterized in that: The cosolvent includes one or more of propylene glycol, ethanol, and glycerol; wherein: the mass percentage of propylene glycol in the composition can be selected from 0-12%, 4.6-12%, 6-12%, 4.6%, 4.7%, 6%, 11%, or 12%; the mass percentage of ethanol in the composition can be selected from 0-20%, 0-19.8%, 18.3-19.8%, 18.3%, 18.5%, or 19.8%; and the mass percentage of glycerol in the composition can be selected from 0-5%, 0-3%, 0-2.5%, 0-2.2%, or 2.2%. The composition according to claim 17, characterized in that: The tackifier includes polyethylene glycol and / or pectin, wherein the polyethylene glycol may include PEG3350 and / or PEG400; wherein the mass percentage of PEG3350 in the composition may be 0-5%, 2.5%-5%, 2.5%, 4.6%, 4.7% or 5%, the mass percentage of PEG400 in the composition may be 0-15% or 15%, and the mass percentage of pectin in the composition may be 0-1% or 0.7%. The composition according to claim 17, characterized in that, It also includes any one or a combination of two or more of the following components: The composition according to claim 22, characterized in that: The stabilizer includes edetate, which includes disodium edetate and / or dipotassium edetate. The disodium edetate content in the composition can be selected as 0-0.1% or 0.05% by mass. The preservative includes benzalkonium chloride, which can be selected as 0-0.02% or 0.02% by mass. The pH adjuster includes one or more of sodium hydroxide, potassium hydroxide, meglumine, citric acid, and hydrochloric acid. The amount of pH adjuster added can be selected to adjust the pH of the composition to 4.1-6.0, 4.5-6.0, 5.0-6.0, 4.1, 4.5, 4.9, 5.0, 5.1, 5.3, or 6.

0. The meglumine content in the composition can be selected as 0-0.5%, 0.02%, 0.25%, or 0.5% by mass. The citric acid can be selected as a 1M citric acid solution. The composition according to claim 23 may optionally contain a pH buffer, which may include one or more of a citrate buffer, a phosphate buffer, and an acetate buffer. The composition according to claim 17, characterized in that: The composition does not contain sodium sulfite or sodium bisulfite. The composition according to claim 17, characterized in that: The composition comprises quetiapine fumarate, a solubilizer, a cosolvent, a thickener, and water. The solubilizer is benzyl alcohol, and the cosolvent is one or a combination of two or more of propylene glycol, ethanol, and glycerol, preferably propylene glycol. The thickener is PEG3350 and / or PEG400. The composition may also optionally contain one or a combination of two or more of benzalkonium chloride, a pH adjuster, and a pH buffer. A quetiapine nasal spray comprising the composition according to any one of claims 1-26 and a metered-dose nasal spray device for administering the composition into the nasal cavity, wherein the volume of composition delivered per spray by the metered-dose nasal spray device is optionally 25-200 μL, 50-150 μL, 25 μL, 50 μL, 75 μL, 100 μL, 125 μL, 150 μL, 175 μL, or 200 μL. The use of the composition according to any one of claims 1-26 or the quetiapine nasal spray according to claim 27 in the preparation of a medicament for treating mental disorders.